Data from Asian and Latin American subjects with inadequate response to MTX were pooled from the APPEAL ( ETN 25 mg biweekly + MTX or csDMARD + MTX ; NCT00422227 ) and Latin RA ( ETN 50 mg/week + MTX or csDMARD + MTX ; NCT00848354 ) studies .